Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -30.29% is 61% above its 5-year average of -77.02%, near the high end of its 5-year range (-119.97%–-30.29%).
65.13% above its 12-month average of -86.87%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -5.38%.
RETURN ON ASSETS (ROA)
-30.29%
RETURN ON ASSETS (ROA) AVG TTM
-86.87%
RETURN ON ASSETS (ROA) AVG 3Y
-85.61%
RETURN ON ASSETS (ROA) AVG 5Y
-77.02%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+65.13%
CURRENT VS 3Y AVG
+64.62%
CURRENT VS 5Y AVG
+60.67%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+6.05%
vs the sector median at left
Phathom Pharmaceuticals, Inc.
Market Cap
$543.65M
Return on Assets (ROA)
-30.29%
TTM Avg
-86.87%
3Y Avg
-85.61%
5Y Avg
-77.02%
Market Cap
$544.37M
Return on Assets (ROA)
-13.22%
TTM Avg
-17.80%
3Y Avg
-57.37%
5Y Avg
-51.87%
Market Cap
$541.33M
Return on Assets (ROA)
-23.82%
TTM Avg
-68.22%
3Y Avg
-60.20%
5Y Avg
-44.39%
Market Cap
$536.32M
Return on Assets (ROA)
-34.82%
TTM Avg
-17.21%
3Y Avg
-15.93%
5Y Avg
-60.12%
Market Cap
$536.04M
Return on Assets (ROA)
-124.45%
TTM Avg
-92.75%
3Y Avg
-98.77%
5Y Avg
-98.11%
Market Cap
$535.43M
Return on Assets (ROA)
0.39%
TTM Avg
-16.14%
3Y Avg
-90.03%
5Y Avg
-84.55%
Market Cap
$560.00M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$561.67M
Return on Assets (ROA)
-20.89%
TTM Avg
7.49%
3Y Avg
-5.84%
5Y Avg
-12.60%
Market Cap
$526.07M
Return on Assets (ROA)
-16.69%
TTM Avg
-61.13%
3Y Avg
-63.72%
5Y Avg
-100.27%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | $543.65M | -30.29% | -86.87% | -85.61% | -77.02% |
| Monopar Therapeutics Inc. (MNPR)vs › | $544.37M | -13.22% | -17.80% | -57.37% | -51.87% |
| Shattuck Labs, Inc. (STTK)vs › | $541.33M | -23.82% | -68.22% | -60.20% | -44.39% |
| ProKidney Corp. (PROK)vs › | $536.32M | -34.82% | -17.21% | -15.93% | -60.12% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $536.04M | -124.45% | -92.75% | -98.77% | -98.11% |
| Delcath Systems, Inc. (DCTH)vs › | $535.43M | 0.39% | -16.14% | -90.03% | -84.55% |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $561.67M | -20.89% | 7.49% | -5.84% | -12.60% |
| Immix Biopharma, Inc. (IMMX)vs › | $526.07M | -16.69% | -61.13% | -63.72% | -100.27% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $523.04M | -42.15% | -50.20% | -44.84% | -47.93% |
ROA
-30.3%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -85.37% |
| 2024-12-31 | -88.37% |
| 2023-12-31 | -48.71% |
| 2022-12-31 | -119.97% |
| 2021-12-31 | -75.96% |
| 2020-12-31 | -43.74% |
| 2019-12-31 | -81.56% |
| 2018-12-31 | -142.79% |
